Sandbox:Zahir: Difference between revisions
Line 195: | Line 195: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;"|Barium enema | ! style="background: #4479BA; color: #FFFFFF; text-align: center;"|Barium enema | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;"|CT scan | ! style="background: #4479BA; color: #FFFFFF; text-align: center;"|CT scan | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Ultrasound | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;"|Others | ! style="background: #4479BA; color: #FFFFFF; text-align: center;"|Others | ||
| style="background: #4479BA; color: #FFFFFF; text-align: center;"|'''Gold standard''' | | style="background: #4479BA; color: #FFFFFF; text-align: center;"|'''Gold standard''' | ||
Line 200: | Line 201: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Prostate cancer | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Prostate cancer | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 219: | Line 221: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Fecal impaction | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Fecal impaction | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 238: | Line 241: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Anal stenosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Anal stenosis | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 257: | Line 261: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Hypertrophied anal papillae | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Hypertrophied anal papillae | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 276: | Line 281: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Endometriosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Endometriosis | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 295: | Line 301: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Uterine malignancy | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Uterine malignancy | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 328: | Line 335: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;"|Barium enema | ! style="background: #4479BA; color: #FFFFFF; text-align: center;"|Barium enema | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;"|CT scan | ! style="background: #4479BA; color: #FFFFFF; text-align: center;"|CT scan | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Ultrasound | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;"|Others | ! style="background: #4479BA; color: #FFFFFF; text-align: center;"|Others | ||
| style="background: #4479BA; color: #FFFFFF; text-align: center;"|'''Gold standard''' | | style="background: #4479BA; color: #FFFFFF; text-align: center;"|'''Gold standard''' | ||
Line 333: | Line 341: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Cervical malignancy | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Cervical malignancy | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 352: | Line 361: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Metastases | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Metastases | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 371: | Line 381: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Pelvic abscess | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Pelvic abscess | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 390: | Line 401: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Pelvic sarcoma | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Pelvic sarcoma | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 409: | Line 421: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Parasacral neurogenic tumor | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Parasacral neurogenic tumor | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | |
Revision as of 21:10, 22 January 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Zahir Ali Shaikh, MD[2]
Differentiating [Disease name] from other Diseases
[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
OR
[Disease name] must be differentiated from [differential dx1], [differential dx2], and [differential dx3].
OR
As [disease name] manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. [Subtype name 1] must be differentiated from other diseases that cause [clinical feature 1], such as [differential dx1] and [differential dx2]. In contrast, [subtype name 2] must be differentiated from other diseases that cause [clinical feature 2], such as [differential dx3] and [differential dx4].
Differentiating [disease name] from other diseases on the basis of [symptom 1], [symptom 2], and [symptom 3]
On the basis [symptom 1], [symptom 2], and [symptom 3], [disease name] must be differentiated from [disease 1], [disease 2], [disease 3], [disease 4], [disease 5], and [disease 6].
Diseases | Clinical manifestations | Diagnosis | Gold standard | Additional findings | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | |||||||||||||||||
Lab Findings | Imaging | Others | ||||||||||||||||
Abdominal pain | Bowel habits | Blood in stool | Weight loss | General appearance | Abdominal exam | Rectal exam | Genitourinary exam | CBC | Tumor markers | Stool test | Colonoscopy | Barium enema | CT scan | Ultrasound | ||||
Rectal carcinoma | LLQ | Constipation | + | + |
|
|
|
NL | Anmeia |
|
FOBT + | localization & biopsy of lesion | Apple core apearance | determine tumor stage | ||||
Rectal polyp | ||||||||||||||||||
Anal cancer | ||||||||||||||||||
Hemorrhoids | ||||||||||||||||||
Rectal intususception | ||||||||||||||||||
Foreign body | ||||||||||||||||||
Diseases | Abdominal pain | Bowel habits | Blood in stool | Weight loss | General appearance | Abdominal exam | Rectal exam | Genitourinary exam | CBC | Tumor markers | Stool test | Colonoscopy | Barium enema | CT scan | Ultrasound | Others | Gold standard | Additional findings |
Prostate cancer | ||||||||||||||||||
Fecal impaction | ||||||||||||||||||
Anal stenosis | ||||||||||||||||||
Hypertrophied anal papillae | ||||||||||||||||||
Endometriosis | ||||||||||||||||||
Uterine malignancy | ||||||||||||||||||
Diseases | Abdominal pain | Bowel habits | Blood in stool | Weight loss | General appearance | Abdominal exam | Rectal exam | Genitourinary exam | CBC | Tumor markers | Stool test | Colonoscopy | Barium enema | CT scan | Ultrasound | Others | Gold standard | Additional findings |
Cervical malignancy | ||||||||||||||||||
Metastases | ||||||||||||||||||
Pelvic abscess | ||||||||||||||||||
Pelvic sarcoma | ||||||||||||||||||
Parasacral neurogenic tumor |